Predict your next investment

HEALTHCARE | Biotechnology
rqxpharmaceuticals.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$1M

About RQx Pharmaceuticals

RQx Pharmaceuticals is a biopharmaceutical company developing broad spectrum antibiotics. The Company endeavors to optimize natural product chemical scaffolds using medicinal chemistry techniques to generate broad spectrum antibiotics. RQx is focused on a novel molecular target for which no antibiotic has been developed. Additionally, RQx has generated proprietary molecules based on a novel chemical scaffold. RQx and its technologies are a strong response to the world's growing need for new antibiotics (due to resistance) and the lack of success with small molecules over the past 20 years. The Company's initial products will focus on community and hospital associated infections, including those from gram-negative bacteria. The Company was founded based on important discoveries in Floyd Romesberg's lab at the The Scripps Research Institute in La Jolla, CA.

RQx Pharmaceuticals Headquarter Location

11099 N. Torrey Pines Road Suite 290

La Jolla, California, 92037,

United States

Latest RQx Pharmaceuticals News

RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug

Jun 2, 2017

LA JOLLA, Calif., Feb. 12, 2013 /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front payment and is eligible to receive research and development milestone payments totaling $111 million. In addition, RQx is eligible to receive royalties on sales of products resulting from the collaboration. "We have made tremendous progress at RQx since the company's founding two years ago, and we are pleased to be moving forward in partnership with Genentech to bring new drugs to market," said Court Turner, CEO of RQx and venture partner at Avalon Ventures. RQx Pharmaceuticals was founded by Avalon Ventures in 2010 with Floyd Romesberg, Ph.D., a professor at The Scripps Research Institute (La Jolla, CA) and two former graduate students of the Romesberg Lab. Avalon Ventures formed the company, then seeded and led the Company's Series A financing, which also included an investment from Correlation Ventures. "We see a unique opportunity to apply Genentech's expertise in drug discovery and development with the innovation and focus of RQx, to develop a new class of novel drug compounds," said James Sabry, senior vice president of partnering at Genentech. About RxQ Pharmaceuticals, Inc. RQx Pharmaceuticals is a biopharmaceutical company developing broad-spectrum small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. To address the growing threat of MDR bacteria, RQx is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe. RQx is inspired by the synergies possible when combining naturally produced antibiotics with modern medical chemistry capabilities and is focused on identifying ideal target/inhibitor combinations to deliver a pipeline of novel antibiotic candidates. SOURCE RQx Pharmaceuticals, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RQx Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RQx Pharmaceuticals is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

RQx Pharmaceuticals Patents

RQx Pharmaceuticals has filed 10 patents.

The 3 most popular patent topics include:

  • Antibiotics
  • Piperazines
  • Antibiotic resistance
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2016

7/27/2021

Antibiotics, Fluoroquinolone antibiotics, Piperazines, Cephalosporin antibiotics, Inflammations

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/21/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/27/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Antibiotics, Fluoroquinolone antibiotics, Piperazines, Cephalosporin antibiotics, Inflammations

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.